share_log

Analyst Ratings For EyePoint Pharmaceuticals

Benzinga ·  Oct 25 22:01  · Ratings

Throughout the last three months, 4 analysts have evaluated EyePoint Pharmaceuticals (NASDAQ:EYPT), offering a diverse set of opinions from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings22000
Last 30D10000
1M Ago01000
2M Ago10000
3M Ago01000

Analysts have set 12-month price targets for EyePoint Pharmaceuticals, revealing an average target of $23.0, a high estimate of $30.00, and a low estimate of $15.00. A 25.81% drop is evident in the current average compared to the previous average price target of $31.00.

bigjpg

Diving into Analyst Ratings: An In-Depth Exploration

In examining recent analyst actions, we gain insights into...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment